Hallo Utrecht! 🇳🇱 Marie & Pauline from our regulatory team are at #TOPRASymposium2026. 🎤 Marie will chair SME4 tomorrow at 11 AM. Let's connect! 🤝 #RegulatoryAffairs #Biotech

Over the past two weeks, our CMO Kali Stasi attended #EURETINA2026 in Vienna and @aao_ophth in New Orleans, connecting with retina specialists, ophthalmologists, researchers and partners. Thank you to all who took the time to connect. #Ophthalmology #GeneTherapy

This week, our team will be in Florence at the 29th EVER Congress, from 15-17 October. We look forward to connecting with experts in the field and sharing clinical updates on our gene-agnostic programs. #GenomicMedicine #Ophthalmology #OcularDisease

Today, we're standing with patients on #WorldSightDay. We’re developing gene-agnostic gene therapies with the goal to preserve, protect, and enhance visual function and slow blinding retinal diseases. Learn more: sparingvision.com/pipeline/

Next month, our team is looking forward to attending various conferences in the US and across Europe, sharing updates on our gene agnostic portfolio. See where we’ll be below👇 #GenomicMedicine #Ophthalmology #OcularDisease

Meet Jérôme Maes, Head of Program Management at SparingVision, driving our gene-agnostic gene therapy programs from concept to patients — with the chance to restore vision for those with inherited retinal diseases. sparingvision.com/blog/ #EmployeeSpotlight

🔬 Patients are at the heart of what we do. From engaging with the patient community at the @RETINAFRANCE conference in Agde to hearing a patient’s personal journey during our annual offsite, these exchanges remind us why our work matters. 💙

After a busy H1 2026 at conferences worldwide, SparingVision looks forward to connecting with the retinal, gene therapy, and investor communities in the next half of 2026. We'll be sharing updates on SPVN06 and SPVN20, our #gene-agnostic programs for retinal diseases. #Conference

Excited to see our CEO Stéphane Boissel featured in @BioCentury 's article looking at the future of RP treatment. Read the full piece here: biocentury.com/article/65971… #GenomeEditing #GenomicMedicines #Ophthalmology #GeneTherapy

Earlier this month, the SparingVision team enjoyed some time together at our summer offsite. A special thank you to @RETINAFRANCE for joining us and sharing valuable patient perspectives. #GenomicMedicines

We are pleased to announce FDA Fast Track designation for our gene agnostic gene therapy SPVN06 in retinitis pigmentosa, highlighting a high unmet medical need and enabling closer FDA interactions to accelerate development. For more information : sparingvision.com/spvn06/

Great month for the SparingVision team at @ARVOinfo. Our CMO, Kali Stasi, joined discussions on retinal innovation, #GeneTherapy, and ocular AAVs for IRDs, plus Prof. Jose-Alain Sahel’s Proctor Award Lecture. Image credit: The Eye & Ear Foundation of Pittsburgh.

🌟Last week, Pierre Axel Vinot, our Senior Director, CMC Portfolio Management, attended #ASGCT in Boston. He presented 2 posters with Genezen. Thanks to ASGCT for inspiring discussions, we are already looking forward to next year! #ASGCT #GeneTherapy #Biotech

🌟We are incredibly proud of our co-founder, Dr. José‑Alain Sahel, honored with the 2026 ARVO Proctor Medal. A well‑deserved honor celebrating decades of breakthrough retinal research and impact for patients. #ARVO #ProctorMedal.

Our CMO Kali Stasi will be at the ARVO annual meeting, the leading global event in ophthalmology and vision research. 📍May 3–7, Denver, CO 👋Feel free to reach out if you’d like to connect! #ARVO2026 #Ophthalmology #Innovation

Proud to be part of the France Deeptech ecosystem 🇫🇷Nearly 300 members across research, startups, investors and industry, working to turn cutting-edge science into real-world impact and future European champions. 👉Learn more : francedeeptech.org #Innovation #FranceDeeptech

At #FranceBioproduction, our Associate Scientist Baptiste Erout spent two days connecting with biotech and academic peers. The event featured informative talks and interactive workshops focused on innovation. Thanks to the organizers and speakers.

Our Associate Scientist, Laboratory operations, Baptiste Erout will be attending the France Bioproduction Congress from 15–16 April. We look forward to two #insightful days exploring the latest scientific and technological advancements. #Ophthalmology

🇬🇧Back from the Advanced Therapies Congress in London. Inspiring discussions on the future of cell & gene therapy. Proud to see our team contribute, including a presentation on new methods to detect replication-competent AAV for ocular gene therapies. #AdvancedTherapies

Our CMO Kali Stasi will be participating in the RBC Capital Markets Virtual Ophthalmology Conference! She will be highlighting SparingVision’s recent progress across our gene-agnostic #gene therapy programs, SPVN06 and SPVN20. #GenomicMedicine